Literature DB >> 17268811

Quantitative exploration of possible reasons for the recent improvement in breast cancer survival.

Sylvie Bérubé1, Louise Provencher, Jean Robert, Simon Jacob, Nicole Hébert-Croteau, Julie Lemieux, Thierry Duchesne, Jacques Brisson.   

Abstract

OBJECTIVE: Breast cancer mortality has been declining in many countries including Canada because of improvements in survival. This study attempts to explain observed trends in breast cancer survival with special attention given to the role of improvements in early detection and treatment.
METHODS: This study is based on 4,312 women diagnosed with primary invasive breast carcinoma treated in a Canadian breast center between 1976 and 2000 and followed to the end of 2001. Observed and relative survival rates were calculated. Multivariate relative survival regression models were used to assess trends in breast cancer survival over the study period.
RESULTS: The proportion of women with small tumors (< or = 10 mm) was higher in late 1990s, while that of women with regional involvement was lower compared to earlier periods. Adjuvant chemotherapy or endocrine therapy use increased steadily from 6.6% to 84.0% during the study period. Five-year relative survival rates ranged between 82.1% and 83.7% between 1976 and 1990, and increased thereafter to reach 87.6% in 1991-95, and 92.1% in 1996-2000. During the first five years after diagnosis, women diagnosed in 1991-95 and 1996-2000 experienced a reduction in breast cancer mortality of 28% (Relative Risk (RR)= 0.72; 95% CI: 0.59-0.89) and 49% (RR = 0.51; 95% CI: 0.39-0.68) respectively compared to women diagnosed in 1976-90. Improvement in breast cancer survival in 1990's could not be explained by characteristics of women, biology of the tumor, advancements in early detection and type of initial treatments.
CONCLUSION: A substantial increase in breast cancer survival was observed in the 1990s but the reasons for this improvement remain elusive. Better knowledge of these reasons could help not only to further reduce the burden related to breast cancer but also the burden related to other major cancer sites.

Entities:  

Mesh:

Year:  2007        PMID: 17268811     DOI: 10.1007/s10549-007-9503-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.

Authors:  Richard Greil
Journal:  Breast Care (Basel)       Date:  2009-06-26       Impact factor: 2.860

2.  Prognostic and predictive value of low estrogen receptor expression in breast cancer.

Authors:  A Bouchard-Fortier; L Provencher; C Blanchette; C Diorio
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

3.  Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.

Authors:  Lu Chen; Hannah M Linden; Benjamin O Anderson; Christopher I Li
Journal:  Breast Cancer Res Treat       Date:  2014-08-28       Impact factor: 4.872

4.  A pan-Canadian prospective study of young women with breast cancer: the rationale and protocol design for the RUBY study.

Authors:  M L Quan; I A Olivotto; N N Baxter; C M Friedenreich; K Metcalfe; E Warner; K MacLennan; J E Stephen; M R Akbari; D Howell; S Narod
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

5.  Breast cancer policy in Latin America: account of achievements and challenges in five countries.

Authors:  Gustavo Nigenda; Maria Cecilia Gonzalez-Robledo; Luz Maria Gonzalez-Robledo; Rosa Maria Bejarano-Arias
Journal:  Global Health       Date:  2016-07-12       Impact factor: 4.185

6.  Event-free survival following early endometrial events in breast cancer patients treated with anti-hormonal therapy: A nationwide claims data study.

Authors:  Yura Lee; Yu Rang Park; Hae Reong Kim; Jong Won Lee
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

Review 7.  Smoking at time of diagnosis and breast cancer-specific survival: new findings and systematic review with meta-analysis.

Authors:  Sylvie Bérubé; Julie Lemieux; Lynne Moore; Elizabeth Maunsell; Jacques Brisson
Journal:  Breast Cancer Res       Date:  2014-04-19       Impact factor: 6.466

8.  Comparative benefit from small tumour size and adjuvant chemotherapy: clues for explaining breast cancer mortality decline.

Authors:  Romano Demicheli; Federico Ambrogi
Journal:  BMC Cancer       Date:  2014-09-24       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.